Product Information:

RESMIROM 80mg Tablets contain Resmetirom 80mg, a selective thyroid hormone receptor-β (THR-β) agonist approved for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), in adults with moderate to advanced liver fibrosis (stages F2–F3).

Resmetirom activates THR-β receptors predominantly in the liver, enhancing mitochondrial fat oxidation, reducing hepatic fat accumulation, and improving inflammation and fibrosis—without significantly affecting the heart or bones (which are regulated by THR-α).

⚠️ Important Note:

Resmetirom (brand name Rezdiffra™) was approved by the U.S. FDA in March 2024 as the first drug specifically for MASH/NASH with fibrosis. The 80mg strength is commonly used as an intermediate or maintenance dose, depending on tolerability and regional prescribing guidelines. As of 2026, it may be available in Pakistan through specialty hepatology or metabolic clinics.

Uses of (RESMIROM 80MG TABLETS):

1. Treatment of biopsy-confirmed or clinically diagnosed MASH/NASH
2. Management of liver fibrosis (F2–F3) associated with obesity, type 2 diabetes, or metabolic syndrome
3. Reduction of hepatic fat, lobular inflammation, hepatocyte ballooning, and fibrosis progression

Key Benefits of (RESMIROM 80MG TABLETS):

1. First-in-class, liver-directed therapy for MASH/NASH
2. Improves liver histology and reduces risk of cirrhosis
3. Lowers LDL cholesterol and triglycerides
4. Oral once-daily dosing with flexible titration options
5. Minimal systemic thyroid-related side effects due to THR-β selectivity

How To Use (RESMIROM 80MG TABLETS):

1. Take once daily with food (to enhance absorption).
2. Swallow whole with water—do not crush or chew.
3. Common dosing regimens:
4. Option 1 (Titration): Start at 60mg/day for 4 weeks, then increase to 80mg/day if 100mg is not tolerated
5. Option 2 (Maintenance): Use 80mg/day as a long-term dose in patients who cannot tolerate 100mg
6. Do not double dose if a dose is missed.

When Not to Use (RESMIROM 80MG TABLETS):

Do not use if you have:

1. Hypersensitivity to resmetirom
2. Severe hepatic impairment (Child-Pugh C)
3. Uncontrolled hyperthyroidism
4. Pregnancy or breastfeeding (safety not established)

Side Effects of (RESMIROM 80MG TABLETS):

Common:

1. Diarrhea, nausea, abdominal discomfort
2. Mild increase in resting heart rate (<5 bpm)
3. Transient elevations in liver enzymes (ALT/AST)

Rare/Serious:

1. Gallstone formation or biliary colic (due to increased cholesterol flux)
2. Myalgia or elevated creatine kinase (CK)
3. Thyroid function alterations (rare; monitor TSH if symptomatic)
4. Discontinue and seek medical evaluation if persistent right upper quadrant pain, jaundice, or unexplained muscle weakness occurs.

Dosage: (RESMIROM 80MG TABLETS):

1. Intermediate/maintenance dose: 80mg once daily with food
2. Titration: May follow 60mg for 4 weeks before escalation
3. Elderly or renal impairment: No dose adjustment needed
4. Hepatic impairment (Child-Pugh A/B): Use with caution; avoid in Child-Pugh C

Who It’s For (RESMIROM 80MG TABLETS):

Adults with confirmed MASH/NASH and liver fibrosis who require effective therapy but cannot tolerate the 100mg dose due to side effects or comorbidities.

Warnings & Precautions:

1. Confirm diagnosis using liver biopsy, FibroScan, or validated serum markers (e.g., ELF, FIB-4)
2. Monitor for gallbladder-related symptoms during therapy
3. Assess ALT, AST, CK, lipids, and TSH at baseline and periodically
4. Combine with lifestyle interventions (weight loss ≥7–10%, glycemic control) for optimal outcomes

Drug Interactions:

1. Statins: Additive LDL-lowering effect (generally beneficial)
2. Strong CYP2C9 inducers (e.g., rifampin): May reduce resmetirom levels
3. No significant interactions with common antidiabetics or antihypertensives
4. Always inform your physician about all medications and supplements.

Additional Information:

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children. Available by prescription only in Pakistan, likely through specialized gastroenterology, hepatology, or metabolic disease centers.